News
Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...
The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback